Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform

• Signs a World-Wide Exclusive License with Stony Brook University for a Novel Platform that can Enhance Radionuclide Targeting
  
  
• Receives up to $2.4M NIH Grant to Develop Differentiated Antibody-based Radiopharmaceutical Approach
  
  

SEATTLE, Feb. 01, 2024 (GLOBE NEWSWIRE) --  -- Perspective Therapeutics, Inc.  (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it has executed an exclusive license agreement with Stony Brook University for the rights to its Cuburbit[7]uril-admantane (CB7-Adma) pre-targeting platform and was awarded the Phase I tranche of a 2.5-year, Fastrack Small Business Innovation Research grant (Phase I $400 thousand; total $2.4 million) from the National Institutes of Health (NIH) National Cancer Institute in support of Perspective’s CB7-Adma host-guest pre-targeting program for the diagnosis and treatment of cancer.

Pre-targeting using the CB7-Adma platform involves two-steps. First, an antibody that binds with high specificity to a cancer-specific protein is administered via intravenous injection. This antibody is chemically modified to include the CB7 chemical entity and accumulates over time at the tumor site. Then, a radionuclide held tightly by Perspective’s proprietary chelator attached to an Adma group is administered. The Adma group binds to the CB7 group that was previously attached to the cancerous cells with remarkable specificity, delivering radiation dose selectively to the tumor sites.

Central to this innovation is CB7-Adma (host-guest) complex formation, driving the interaction between the antibody and radioligand. The chosen host-guest pair, CB7-Adma, demonstrates promising in vivo stability, modularity, and low immunogenicity. The platform's potential was validated through in vivo profiling of ligands, employing a CB7-modified carcinoembryonic antigen (CEA) targeting antibody.

Figure 1. Illustration of the 2-step CB7-Adma pre-targeting approach. (1) a macromolecule that has been chemically modified to include the CB7 handle is administered and allowed to bind to the tumor. (2) The radioligand with fast clearance properties that carries the radionuclide, and the Adma chemical group is administered. The Adma guest ligand binds to the tumor rapidly and unbound radioligand clears the body quickly, thereby optimizing delivery of radioactivity to the tumor, with little interaction with healthy tissue and organs. (Jallinoja et al., J Nucl Med 2023; 64:1203–1209)